Additionally, Kaplan–Meier analysis demonstrated that both SHC1 and p66Shc were significantly associated with the prognosis of GBM patients, with high expression predicting shorter overall survival (OS), progression-free interval(PFS), and disease-specific survival (DSS) (Fig. 7C–E), While the expression levels of p46SHC and p52SHC did not correlate with the expression or survival outcomes of patients with GBM (Supplementary Fig. S1C,D). Here, SHC1 is linked to glioblastoma.